Brigatinib is a next-generation ALK inhibitor that earned FDA approval in 2017 as a second-line therapy after treatment with crizotinib for ALK-positive non-small cell lung cancer. Recently, clinical trial results published ...
May 21, 2019
0
5
(HealthDay)—For patients with locally advanced non-small cell lung cancer (NSCLC), deep-learning networks integrating computed tomography (CT) scans at multiple time points can improve clinical outcome predictions, according ...
May 16, 2019
0
2
Trials with people with newly-diagnosed colorectal and non-small cell lung cancer suggest that whole body MRI could reduce the time it takes to diagnose the stage of cancers. The results are from two prospective trials with ...
May 10, 2019
0
4
University of Texas at Dallas scientists have demonstrated that the growth rate of the majority of lung cancer cells relates directly to the availability of a crucial oxygen-metabolizing molecule.
Apr 22, 2019
0
677
A deep-learning model developed using serial image scans of tumors from patients with non-small cell lung cancer (NSCLC) predicted treatment response and survival outcomes better than standard clinical parameters.
Apr 22, 2019
0
2
A study from the University of Southern California, Keck School of Medicine, sought to examine possible health disparities in the treatment of lung cancer within the Asian community in the U.S. In this study, rates of recommended ...
Apr 09, 2019
0
1
Stereotactic Body Radiotherapy (SBRT), a high-dose, precisely delivered radiotherapy, is considered the standard treatment for patients with medically inoperable, node-negative, non-small cell lung cancer (NSCLC). However, ...
Apr 05, 2019
0
0
Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients who had EGFR-mutant non-small cell lung cancer (NSCLC) that had developed resistance ...
Mar 31, 2019
0
1
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients.
Mar 29, 2019
0
2
UT Southwestern researchers have identified two proteins that act as gatekeepers to dampen a potentially life-threatening immune response to chronic infection.
Mar 22, 2019
0
449
